一种定量临床决策支持策略用于识别口咽头颈癌患者中可能从质子放疗获益最多者
研究利用吞咽困难、食管炎、甲状腺功能减退、口干症和口腔黏膜炎的正常组织并发症概率模型,对33例既往接受光子调强放疗的口咽头颈癌患者估算正常组织并发症概率,并生成质子治疗对比计划。光子与质子放疗平均质量调整生命年损失分别为1.52与1.15,质子平均节省0.37质量调整生命年(复合95%CI 0.27-2.53)。
要点
- 质子放疗较光子调强放疗平均节省0.37质量调整生命年(复合95%CI 0.27-2.53)。
- 长期并发症吞咽困难和口干症对质量调整生命年损失贡献最大。
- 质子放疗节省的质量调整生命年在患者间差异大,范围0.06至0.84。
核心结论
- 该定量决策支持策略可识别可能从质子放疗获益最多的口咽癌患者,但质子治疗的估计获益最终取决于现代光子调强放疗方案可达到的危及器官剂量。
研究设计与样本
- 研究纳入33例既往接受光子调强放疗的口咽头颈癌患者,使用吞咽困难、食管炎、甲状腺功能减退、口干症和口腔黏膜炎的正常组织并发症概率模型进行估算。
- 对比质子治疗计划按合作质子中心头颈放疗临床方案生成,对每例患者进行10000次蒙特卡洛采样以考虑模型参数不确定性。
主要发现
- 基于本机构实际实施的光子调强放疗剂量与可达到的质子治疗剂量,所有头颈放疗并发症导致的平均质量调整生命年损失光子为1.52、质子为1.15,质子平均节省0.37质量调整生命年(复合95%CI 0.27-2.53)。
- 长期并发症吞咽困难和口干症对质量调整生命年损失贡献最大。
- 质子放疗节省的质量调整生命年在患者间差异较大,范围为0.06至0.84质量调整生命年。
- 年轻、p16阳性且吸烟≤10包年的患者可能从质子治疗获益最多,但该发现需在更大患者系列中验证。
- 敏感性分析将所有危及器官的光子调强放疗剂量降低20%后,质子治疗总体估计无获益,节省-0.02质量调整生命年,但部分患者仍有估计获益,范围为-0.50至0.43质量调整生命年。
临床怎么用
- 作者认为这些结果可帮助放射肿瘤科医生和质子治疗中心优化资源分配并改善头颈癌患者的生活质量。
局限性
- 年轻、p16阳性且吸烟≤10包年患者可能获益最多的发现需在更大患者系列中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Developing a quantitative decision-support strategy estimating the impact of normal tissue complications from definitive radiation therapy (RT) for head and neck cancer (HNC). We developed this strategy to identify patients with oropharyngeal HNC who may benefit most from receiving proton RT. METHODS AND MATERIALS: Recent normal tissue complication probability (NTCP) models for dysphagia, esophagitis, hypothyroidism, xerostomia, and oral mucositis were used to estimate NTCP for 33 patients with oropharyngeal HNC previously treated with photon intensity modulated radiation therapy (IMRT). Comparative proton therapy plans were generated using clinical protocols for HNC RT at a collaborating proton center. Organ-at-risk (OAR) doses from photon and proton RT plans were used to calculate NTCPs; Monte Carlo sampling 10,000 times was used for each patient to account for model parameter uncertainty. The latency and duration of each complication were modeled from calculated NTCP, accounting for age-, sex-, smoking- and p16-specific conditional survival probability. Complications were then assigned quality-adjustment factors based on severity to calculate quality-adjusted life years (QALYs) lost from each complication. RESULTS: Based on our institutional-delivered photon IMRT doses and the achievable proton therapy doses, the average QALY reduction from all HNC RT complications for photon and proton therapy was 1.52 QALYs versus 1.15 QALYs, with proton therapy sparing 0.37 QALYs on average (composite 95% confidence interval, 0.27-2.53 QALYs). Long-term complications (dysphagia and xerostomia) contributed most to the QALY reduction. The QALYs spared with proton RT varied considerably among patients, ranging from 0.06 to 0.84 QALYs. Younger patients with p16-positive tumors who smoked ≤10 pack-years may benefit most from proton therapy, although this finding should be validated using larger patient series. A sensitivity analysis reducing photon IMRT doses to all OARs by 20% resulted in no overall estimated benefit with proton therapy with -0.02 QALYs spared, although some patients still had an estimated benefit in this scenario, ranging from -0.50 to 0.43 QALYs spared. CONCLUSIONS: This quantitative decision-support strategy allowed us to identify patients with oropharyngeal cancer who might benefit the most from proton RT, although the estimated benefit of proton therapy ultimately depends on the OAR doses achievable with modern photon IMRT solutions. These results can help radiation oncologists and proton therapy centers optimize resource allocation and improve quality of life for patients with HNC.
引用
- Brodin NP, Kabarriti R, Pankuch M, et al. A Quantitative Clinical Decision-Support Strategy Identifying Which Patients With Oropharyngeal Head and Neck Cancer May Benefit the Most From Proton Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 30496877. doi:10.1016/j.ijrobp.2018.11.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。